The Chinese NDRC fines three manufacturers of an insomnia drug for refusing to supply its pharmaceutical ingredients to other competitors and for raising its prices (Huazhong / Xinyi / Siyao)

China's National Development and Reform Commission (NDRC), one of China’s three agencies responsible for antitrust enforcement, recently published its decisions to fine three Chinese companies active in the manufacture of estazolam (a drug commonly used to treat insomnia) for refusing to supply estazolam active pharmaceutical ingredients (APIs) to other estazolam tablet manufacturers and raising estazolam tablet prices. The conduct was held to have infringed China’s Anti-Monopoly Law (AML) which prohibits, among other things, price-fixing and joint-boycotts. The NDRC imposed total fines of approximately RMB 2.6 million (approximately USD 418,057) on the three companies. The decisions are the latest in a series of antitrust enforcement actions following drug price reforms in China in

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Freshfields Bruckhaus Deringer (London)
  • Freshfields Bruckhaus Deringer (Beijing)
  • Fangda (Hong Kong)
  • Freshfields Bruckhaus Deringer (Beijing)

Quotation

Nicholas French, Ninette Dodoo, Joy Wong, Kailun Ji, The Chinese NDRC fines three manufacturers of an insomnia drug for refusing to supply its pharmaceutical ingredients to other competitors and for raising its prices (Huazhong / Xinyi / Siyao), 22 July 2016, e-Competitions July 2016, Art. N° 94827

Visites 56

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues